A set of ~800 largely isogenic deficiency stocks created by FLP-induced recombination between FRT-carrying transgenic insertions; molecularly defined deletion endpoints correspond to initial location of the progenitor insertions. Designed to fill gaps in deletion coverage and breakpoint placement; also used to replace older available deficiencies that have not been molecularly mapped.
Breakpoint based on progenitor insertion release 3 sequence coordinate 3L:15459907 , per R. Hoskins (Gene Disruption Project) personal communication, mapped forward to release 5.
Breakpoint from FlyBase's release 5 sequence location of progenitor insertion.
The presence of P+PBac{XP5.WH5}BSC732 was verified using the PCR methods and primers described in FBrf0175003.
Exelixis, Inc. determined the insertion site of P{XP}d02504 to be Release 3 genomic coordinate 7828494 on chromosome arm 3L. The Gene Disruption project determined the insertion site of P{XP}d02504 to be Release 3 genomic coordinate 7828548 on arm 3L. This corresponds to 66A17 on the Release 3 and Release 5 genome maps. The predicted position of PBac{WH}DNApol-α50f02992 on the Release 5 map is 66C8. Consequently, the cytological breakpoints of Df(3L)BSC732 are predicted to be 66A17;66C8.